Clinical Trial Update: Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of bortezomib, paclitaxel, and carboplatin in patients with metastatic and intraocular melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Melanoma
• Ciliary Body Melanoma
• Intraocular Melanoma
• Iris Melanoma
• Melanoma

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• CARBOPLATIN (Carboplatin)
• Paclitaxel (Taxol) (paclitaxel)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Status: COMPLETED